Physician profile
Sandra S Charles
NPI 1366187882
$1,451.44
in general payments reported to CMS, 2019-2025
32 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.74 · 2023: $806 · 2024: $445 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051 · Travel and Lodging: $286 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.70 |
| Travel and Lodging | $286.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $389.86 | 2023 | Brukinsa |
| Seagen INC. | $99.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $78.65 | 2023-2024 | Airsupra, Breztri |
| Sumitomo Pharma America, INC. | $74.53 | 2024-2025 | Gemtesa |
| Novo Nordisk INC | $65.29 | 2024-2025 | Rybelsus, Ozempic |
| Janssen Biotech, INC. | $63.72 | 2023-2024 | Imbruvica, Darzalex, Tecvayli |
| Abbvie INC. | $63.10 | 2023-2025 | |
| Lilly USA, LLC | $61.56 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $50.29 | 2024 | Cologuard Collection Kit |
| Corium, LLC | $36.26 | 2024-2025 | Azstarys |
| Pfizer INC. | $33.67 | 2023-2024 | |
| Daiichi Sankyo INC. | $33.30 | 2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.54 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $30.92 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $28.59 | 2024-2025 | Trelegy Ellipta, Rotarix, Pediarix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $25.85 | 2023 | Ruconest |
| Astellas Pharma US INC | $24.65 | 2025 | Veozah |
| G1 Therapeutics, INC. | $22.40 | 2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $21.81 | 2023 | Monoferric |
| Otsuka America Pharmaceutical, INC. | $21.42 | 2024 | Rexulti |
| Acrotech Biopharma INC. | $19.26 | 2023 | Beleodaq |
| Regeneron Healthcare Solutions, INC. | $18.59 | 2023 | Libtayo |
| Aadi Bioscience, INC. | $18.56 | 2023 | Fyarro |
| Eisai INC. | $17.89 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2024 | |
| Cti Biopharma Corp. | $15.74 | 2022 | |
| Morphosys, US INC. | $15.06 | 2023 | Monjuvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2025 | Trintellix |
| Amgen INC. | $14.28 | 2023 | Lumakras |
| Genentech USA, INC. | $14.02 | 2023 | Rozlytrek, Alecensa, Gavreto |
| Dexcom, INC. | $13.95 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.